Medindia

X

Progression-Free Survival Advantage Seen in Patients With Pancreatic Cancer With Sutent

by Rajshri on  January 25, 2010 at 9:51 PM Drug News   - G J E 4
 Progression-Free Survival Advantage Seen in Patients With Pancreatic Cancer With Sutent
Results from a randomized phase 3 trial of Sutent (sunitinib malate) indicate that patients with pancreatic neuroendocrine tumours are able to live longer if they take the medication as compared with patients treated with placebo, Pfizer Inc has announced.
Advertisement

"This trial advances our understanding of the use of novel targeted therapies in a patient population with limited treatment options," said Dr. Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer's Oncology Business Unit. "We are pleased to be working toward filling an unmet patient need, as we did with Sutent four years ago in patients with kidney cancer and gastrointestinal stromal tumours."

Advertisement
In February 2009, an independent Data Monitoring Committee (DMC) had suggested that the trial be halted as the drug showed significant benefits for patients with pancreatic cancer. Pfizer has filed applications with the regulatory bodies in US, Europe and Canada asking for permission to sell the drug for pancreatic neuroendocrine tumours.

The details of the phase 3 study were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium.




Source: Medindia
RAS
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All